| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 52(3); 2020 > Article
Weng, Yao, Xu, Hu, Yao, Liu, Wu, Tang, Fu, Wang, and Yao: RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer



Triple-negative breast cancer (TNBC) is highly malignant and has poor prognosis and a high mortality rate. The lack of effective therapy has spurred our investigation of new targets for treating this malignant cancer. Here, we identified RON (macrophage-stimulating 1 receptor) and MET (MET proto-oncogene, receptor tyrosine kinase) as a prognostic biomarker and therapeutic targets for potential TNBC treatment.

Materials and Methods

We analyzed RON and MET expression in 187 primary TNBC clinical samples with immunohistochemistry. We validated the targeted therapeutic effects of RON and MET in TNBC using three tyrosine kinase inhibitors (TKIs): BMS-777607, INCB28060, and tivantinib. The preclinical therapeutic efficacy of the TKIs was mainly estimated using a TNBC xenograft model.


Patients with TNBC had widespread, abnormal expression of RON and MET. There was RON overexpression, MET overexpression, and RON and MET co-overexpression in 63 (33.7%), 63 (33.7%), and 43 cases (23.0%), respectively, which had poor prognosis and short survival. In vivo, the TKI targeting RON ant MET inhibited the activation of the downstream signaling molecules, inhibited TNBC cell migration and proliferation, and increased TNBC cell apoptosis; in the xenograft model, they significantly inhibited tumor growth and shrank tumor volumes. The TKI targeting RON and Met, such as BMS-777607 and tivantinib, yielded stronger anti-tumor effects than INCB28060.


RON and MET co-overexpression can be significant pathological characteristics in TNBC for poor prognosis. TKIs targeting RON and MET have stronger drug development potential for treating TNBC.


Triple-negative breast cancer (TNBC) is a breast cancer subtype that does not express estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2; its characteristics are earlier age of onset, greater metastatic potential, is highly malignant, poor prognosis, and a high mortality rate [1,2]. At present, TNBC treatment mainly involves chemotherapy, and a considerable number of patients experience toxic adverse effects; moreover, given blind chemotherapy, drug resistance is easily developed and the recurrence rate is high. Therefore, the search for a new treatment target in TNBC is presently one of the most important clinical requirements.
Receptortyrosine kinase (RTK) including MET (MET protooncogene, receptor tyrosine kinase), AXL, epidermal growth factor receptor and so on is a high affinity cell surface receptor for many polypeptide, growth factors, cytokines, and hormones that plays a key role in the development and progression of many types of cancer [3]. The MET (MET protooncogene, RTK) proto-oncogene family is found on the long arm of human chromosome 7, and the protein product is an RTK [4]. The family has two members: RON (macrophagestimulating 1 receptor) and MET. MET plays an important role in cell proliferation, differentiation, carcinogenesis, and invasion and migration [5]. RON is a specific cell membrane receptor for human macrophage-stimulating protein (MSP) [6]. MET is a receptor for hepatocyte growth factor (HGF) [7].
RON has been implicated as playing an important role in the development of various tumors, including pancreatic cancer, colorectal cancer, non-small cell lung cancer, and prostate cancer [6]. Abnormal expression of RON has also been detected in clinical samples of primary breast cancer [8,9]. Subsequent molecular mechanism experiments have shown that abnormal RON expression leads to hyperphosphorylation of RON kinase, which activates various intracellular signaling cascades downstream [8,10,11]. These lead to increased cell proliferation, migration, invasion, and drug resistance. In addition, abnormal RON expression is a therapeutic target in breast cancer that many small-molecule inhibitors of RON are undergoing preclinical and clinical evaluation [8,12-14]. The preliminary results indicate that inhibiting RON signaling has the potential for treating TNBC. At present, there is a lack of research on the role of RON in TNBC, and the mechanism remains unknown.
Similarly, aberrant activation of MET is frequently found in tumors, including mutations, gene amplification, increased transcription, and enhanced ligand activation [7]. Some studies have found frequent MET overexpression in invasive breast cancer [15,16]. These studies suggest that MET activation and overexpression can be an independent risk factor in breast cancer. Based on related research on RON and MET in primary breast cancer, we are committed to exploring whether RON and MET also play important roles in TNBC [17,18].
Currently, small-molecule tyrosine kinase inhibitors (TKIs) against the MET proto-oncogene family are widely used. Due to the existence of a signal cross-talk mechanism between RON and MET, most TKIs can inhibit both RON and MET, and a small proportion can only inhibit MET alone, while almost no TKIs inhibit RON alone [6,19]. Among the TKIs, BMS-777607 is a MET-related inhibitor that acts on c-Met, Axl, Ron, and Tyro3 [20,21]. And it has a stronger inhibitory effect on RON than on MET; its half maximal inhibitory concentration (IC50) in cell-free testing is 1.8 nM (RON) and 3.9 nM (MET) [20]. INCB28060 is a novel adenosine triphosphate (ATP)-competitive MET inhibitor with a cell-free assay IC50 of 0.13 nM and no activity against RON [22]. Tivantinib (ARQ 197) is the first non-ATP–competitive MET inhibitor with a cell-free assay inhibitory constant (Ki) of 0.355 μM with little activity against RON [23].
The present study was designed to determine RON and MET expression in primary TNBC samples and to evaluate their potential as a predictive prognostic biomarker of TNBC. Our rationale is that understanding RON and MET expression in TNBC can aid dissection of the molecular mechanisms underlying TNBC malignancy and identify a new treatment strategy for TNBC.

Materials and Methods

1. Cell lines and reagents

The TNBC cell lines HCC1806, HCC2185, MDA-MB-231, and SUM52PE were from American Type Cell Culture (ATCC, Manassas, VA). All cell lines were authenticated in 2015 with cytogenesis analysis. The cell lines were cultured and supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO2 at 37°C. Mouse antiRON mAb (Zt/g4 and Zt/f2) and rabbit anti-RON (5029) antibody were used as previously described [8,24]. Human mature MSP and HGF were from R&D Systems (Minneapolis, MN). Phosphorylated (phospho)-tyrosine mouse mAb, phospho-MET, AKT, phospho-AKT, extracellular signal–regulated kinase (ERK) 1/2, and phospho-ERK1/2 were from Cell Signaling Technology (CST, Danvers, MA). All TKIs were from MedchemExpress (MCE, Monmouth Junction, NJ). BMS-677007, INCB28060, and tivantinib were dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 10 mM and stored at –20°C.

2. Patients and tissue specimens

We analyzed 187 patients pathologically diagnosed with TNBC between May 2011 and October 2015 at The First Affiliated Hospital, Zhejiang University School of Medicine. All patients underwent pathological biopsy for breast cancer surgery. The clinical parameters included patient demographics, tumor-node-metastasis (TNM) stage, tumor differentiation, tumor size, and treatment modality. All tissues were fixed in 10% buffered formalin and embedded in paraffin. Immunohistochemical (IHC) staining was carried out using Zt/f2 for RON as described previously and using rabbit anti-MET mAb for MET, followed by reagents from Envision System (Dako, Carpentaria, CA) [24]. Two pathologists reviewed all archival hematoxylin and eosin–stained sections. This method combines scores from staining intensity (0-3) and the proportion of stained cells (0-4). A combined score of 2-4 was deemed weakly positive, while a combined score ≥ 5.0 was considered high expression or overexpression. Patients with RON overexpression and MET overexpression were considered to have co-overexpression.

3. Flow cytometry

Individual TNBC cell lines were digested before immunofluorescence staining antibody treatment. Surface RON was detected using Zt/g4 after combination with anti-mouse IgG conjugated with Alexa Fluor 488 (BD, New York, NY); MET was detected using anti-MET mAb conjugated with BV510 (BD). Normal mouse IgG was used as the isotype control. All flow cytometry experiments were performed using BD FACSCanto II (BD).

4. Cell viability and cellular caspase-3/7 activity assays for apoptosis

HCC1806, HCC2185, SUM52PE, and MDA-MB-231 cells (8,000 cells per well in 96-well plates in triplicate) were treated with different concentrations of BMS-777607, INCB28060, or tivantinib for 96 hours. Cell viability after TKI treatment was determined using Cell Counting Kit-8 (CCK-8; MCE). DMSO-treated cells were used as the control. Caspase-3 and caspase-7 activity was measured using the caspase-Glo 3/7 assay system (Promega, Madison, WI) according to the manufacturer’s instructions. The results are expressed as the fold induction of the control (caspase-3/7 activity of the control cells was set as 1).

5. Phosphorylation and western blotting

MDA-MB-231 cells were treated with the IC50 of BMS-777607, INCB28060, or tivantinib in serum-free medium. The phosphorylation assay was performed by stimulating the cells (2×106 cells/mL/sample) with 2 nM MSP and HGF at 37°C for 15 minutes. The cells were lysed in radioimmunoprecipitation (RIPA) buffer and separated by 8% sodium dodecyl sulfate–polyacrylamide electrophoresis (20 μg per sample) under reduced conditions. RON, MET, downstream pathway proteins including AKT and ERK1/2, and the phosphorylated proteins were detected using rabbit mAb as described above and visualized using enhanced chemiluminescent reagents. Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control to ensure equal sample loading.

6. Cell motility assay

Cell motility was analyzed by treating MDA-MB-231 cells (2×105 cells per well in 6-well plates) with TKIs for 24 hours. The cells were serum-starved overnight and scratched to generate artificial gaps. The cells were treated with the IC50 of BMS-777607, INCB28060, or tivantinib in serum-free medium. Cell motility was monitored, and cells that had migrated into the denuded area were scored. Images were collected at 0, 6, 12, and 24 hours under an inverted microscope (Zeiss, Jena, Germany).

7. TNBC xenograft mouse model and TKI treatment

Female athymic nude mice (6 weeks old) were purchased from Shanghai Laboratory Animal Center, injected with 1×107 TNBC cells in the right subcutaneous space, and randomly divided into different groups (n=4 per group). Treatment was initiated when the average tumor volume was 100-150 mm3. Tumor-bearing mice were dosed orally by gavage daily with 25 mg/kg BMS-777607, 10 mg/kg INCB28060, or 20 mg/kg tivantinib for up to 15 days. Tumor volume (V) was measured every 3 days and calculated as follows: V=(length×width2)/2. Tumor growth was monitored for 51 days. Animals were euthanized when tumor volumes were > 2,000 mm3 or if the tumors became necrotic or ulcerated through the skin.

8. Statistical analysis

GraphPad Prism 7 (GraphPad Software, San Diego, CA) and SPSS ver. 17.0 (SPSS Inc., Chicago, IL) were used for statistical analysis. The relationships between RON and MET expression and the clinicopathologic characteristics were compared using the chi-square test, one-way analysis of variance (ANOVA), or the two independent samples t test. Overall survival (OS) was calculated as the time from diagnosis of TNBC until death or the date of the last follow-up. Survival data were analyzed by the Kaplan-Meier method and log-rank test. Results are reported as the mean±SD. The control and treatment group data were compared using Student’s t test. Statistical differences at p < 0.05 were considered significant.

9. Ethical statement

All mouse experiments were approved by the institutional animal care committee of The First Affiliated Hospital, Zhejiang University School of Medicine (reference numbers: 2017400-2).


1. Clinical characteristics of patients

The clinical features of the 187 TNBC cases are as follows (Table 1): the patients were aged 27-83 years; the mean age was 52.82±12.44 years. The TNM stage distribution was: stage I, 85 cases (45.5%); stage II, 85 cases (45.5%); stage III, 17 cases (9.1%). Most patients (n=147, 78.6%) had poor pathological grading. Among the remaining patients, one case (0.5%) was well-differentiated, and 20 cases (10.7%) were moderately differentiated. The differentiation of the remaining 19 cases (10.2%) was unknown. One hundred and sixty-one patients (86.1%) received chemotherapy while the others did not. Forty-eight patients (25.7%) had lymph node metastasis during follow-up. Distance metastasis was confirmed in 19 patients (10.2%) during follow up.

2. RON and MET expression in TNBC

RON and MET staining were detected in the cell membrane and cytoplasm of cancer cells, while that of paracancerous cells were weakly stained. RON and MET immunoreactivity, shown by the different staining intensities, is shown in Fig. 1. One hundred and forty-seven cases (78.6%) were RON-positive; 63 cases (33.7%) had RON overexpression. One hundred and fifty-three cases (81.8%) and 63 cases (33.7%) were MET-positive and MET-overexpressing, respectively. One hundred and twenty-seven cases (67.9%) and 43 cases (23.0%) were RON/MET co-positive and RON/MET co-overexpressing, respectively. IHC scoring showed that RON and MET expression were correlated (Pearson correlation analysis, p < 0.01) (S1 Table). Table 1 summarizes the information on RON and MET expression in the TNBC samples. However, IHC staining confirmed that RON and MET were widely expressed in patients of different ages, TNM stage, pathological grade, and primary TNBC with or without distant or lymph node metastasis.

3. Relationship between RON and MET expression and OS

The role of RON and MET expression in OS was assessed using Kaplan-Meier analysis and the log-rank test (Fig. 2). We analyzed a total of 176 patients after excluding patients with other tumors or systemic diseases (such as cirrhosis, uncontrollable diabetes or hypertension, etc.). All patients were followed until May 2018. The 5-year survival rate of all patients was 83.9±3.1% while the 3-year survival rate of all patients was 88.4±2.4%. RON and MET expression levels were significantly correlated with patients' OS (p < 0.05 and p < 0.01 correspondingly). Patients with RON high-expression tumors had significantly worse 5-year survival rate (73.4%±6.3%) than patients with RON low-expression tumors (89.2%±3.2%) (Fig. 2A). Similarly, there was poorer survival among patients with MET high-expression tumors compared with patients with MET low-expression tumors (5-year survival rate, 76.1%±5.8% vs. 87.6%±3.5%) (Fig. 2B). To assess the relative importance of RON and MET co-expression, we combined the two biomarkers to evaluate their association with survival (Fig. 2C and D) and found that patients with RON+/MET+ tumors had worse survival compared with patients with RON–/MET–tumors (5-year survival rate: 73.5%±7.7% vs. 90.0%±3.5%, p < 0.01). The 5-year survival rate in patients with RON+/MET–tumors and RON–/MET+ tumors was 73.3%±10.6% and 80.7%±8.7%, respectively.

4. RON and MET expression in TNBC cell lines

The significance of RON and MET in the TNBC samples prompted us to determine if breast cancer cell lines also express RON and MET (S2 Fig.). Among the four TNBC cell lines, RON was expressed in SUM52PE, HCC2185, and MDA-MB-231 cells, while MET was expressed only in MDA-MB-231 cells.

5. TKIs inhibited TNBC cell proliferation modestly and induced apoptosis

The TNBC cell lines were incubated with BMS-777607, INCB28060, or tivantinib for 96 hours. Fig. 3A shows the effect of the TKIs on TNBC cell viability. BMS-777607 and tivantinib reduced HCC2185, SUM52PE, and MDA-MB-231 cell viability significantly and in a dose-dependent manner. The IC50 of BMS-777607 were 1.925 μM, 3.727 μM, and 2.273 μM for HCC2185, SUM52PE, and MDA-MB-231, respectively. The IC50 of tivantinib were 0.5339 μM, 0.3656 μM, and 0.7293 μM for HCC2185, SUM52PE, and MDA-MB-231, respectively. Compared with the other two TKIs, INCB28060 had a weaker inhibitory effect, and its IC50 was > 10 μM for the HCC2185, SUM52PE, and MDA-MB-231 cells that was considered of no statistical significance. At 0-10 μM, all three TKIs had no significant effect on the growth of HCC1806 cells, which do not express RON or MET.
We also tested the effect of TKIs on TNBC cell apoptosis. Fig. 3B shows the apoptosis activity in the cell lines. BMS-777607 and tivantinib increased HCC2185, SUM52PE, and MDA-MB-231 cell apoptosis significantly in a dose-dependent manner. The median effect concentration (EC50) of BMS-777607 were 7.816 μM, 7.778 μM, and 2.766 μM for HCC2185, SUM52PE, and MDA-MB-231, respectively. The EC50 tivantinib were 0.2427 μM, 1.079 μM, and 0.3446 μM for HCC2185, SUM52PE, and MDA-MB-231 cells, respectively, while there was no significant difference in apoptosis between the 0-10 μM INCB28060 groups.

6. TKIs suppressed cell migration

All three TKIs significantly suppressed cell motility at their respective IC50 from 0 hour until 24 hours (Fig. 4). At this dose, the 24-hour mobility of cells treated with BMS-777607, INCB28060, and tivantinib was 44.15% (p < 0.001), 62.43% (p < 0.001), and 21.91% (p < 0.001), respectively, compared with the 95.99% in the control group. Compared with BMS-777607 and tivantinib, INCB28060 caused less inhibition of MDA-MB-231 cell migration (p < 0.001).

7. TKIs inhibited the RON- and MET-induced signaling pathways

MDA-MB-231 cells were treated with the TKIs at their respective IC50 for 30 minutes or 60 minutes and evaluated by western blotting (Fig. 5). BMS-777607 inhibited RON and MET phosphorylation, and the phosphorylation signals of downstream AKT and ERK1/2 were almost completely inhibited, while their total protein was unchanged. In contrast, INCB28060 only inhibited MET phosphorylation, and its inhibition of AKT and ERK1/2 phosphorylation was weaker than that of BMS-777607. On the other hand, tivantinib inhibited the basal levels of phosphorylated RON and MET within 30 minutes. Compared with BMS-677077, it did not obviously inhibit AKT and ERK1/2.

8. Therapeutic activity of TKIs in TNBC xenograft model

Of the four TNBC cell lines tested, HCC1806 and MDA-MB-231 cells could grow in athymic nude mice and were selected for the therapy studies. In our mouse tumor-bearing model, HCC2185 and SUM52PE cells did not successfully form tumors, which is both consistent with some studies [25] and inconsistent with others [26]. The HCC1806 cell–initiated xenografts grew rapidly and were insensitive to all three TKIs (Fig. 6A). The control and experimental groups had a tumor volume of 2,000 cm3 at around day 15 of dosing. After the mice had been sacrificed by cervical dislocation, the tumor tissues were removed; the tumor mass between the groups was not statistically significantly different. For MDA-MB-231 cells, INCB28060 could delay tumor volume to 2,000 cm3 (30 days vs. 27 days) while the tumor mass was not statistically significant (0.87±0.20 g vs. 1.20±0.12 g). BMS-777607 and tivantinib reduced the tumor significantly, and the average tumor volume was < 200 mm3 by 15 days. After treatment had been halted, the tumor growth rate of the BMS-777607 and tivantinib groups was slower than that of the control group. Fig. 6B shows the tumors obtained from the mice. Compared with the control group, the tumor growth reduction rate in the BMS-777607 group was 92.5% (p < 0.001); that in the tivantinib group was 65.8% (p < 0.001). Tumors in the tivantinib group grew faster than that in the BMS-777607 group (p < 0.001).


The present study is our first attempt to analyze RON and MET expression in a large number TNBC samples. We show that RON and MET were widely overexpressed in TNBC samples regardless of patient age, pathological grade, clinical stage, metastasis, and tumor size. In our study, patients with RON overexpression tended to have higher Met expression, and vice versa, which encouraged us to study the cross-talk between RON and MET.
In the survival analysis, our studies suggest that RON and MET may be involved in an important process in the malignant progression of TNBC. Therefore, abnormal RON and MET could be used as biomarkers of poor prognosis in TNBC. Among the four groups, the 5-year survival rate of RON+/MET+ patients was significantly lower than that of RON+/MET–, RON–/MET+, and RON–/MET–. This prompted us to combine the two targets of RON and MET to comprehensively assess the prognosis of triple-negative breast cancer patients, not just in breast cancer [15]. With the gradual popularization of molecular diagnostics, we believe that detecting RON and MET expression in patients with TNBC in clinical practice would greatly important for predicting the malignant behavior of cancer.
Targeted RON TKIs require targets to have important physiological significance in tumor development [25]. As TKIs rarely inhibit RON alone, we selected BMS-777607 for the present study. Due to the much stronger inhibition of RON than MET, we believe that BMS-777607 can inhibit RON and MET, in which inhibition of RON plays a major role [20].
First, in the cell proliferation experiment, BMS-777607 significantly inhibited the proliferation efficiency of the RON-positive HCC2185, SUM52PE, and MDA-MB-231 cells with a dose-related correlation. The apoptosis experiments suggest that BMS-777607 inhibits cell proliferation by inducing apoptosis. The cell migration experiments confirmed that BMS-777607 can inhibit RON-mediated cell migration and invasiveness.
Second, BMS-777607 inhibited RON phosphorylation, and the phosphorylation signals of the downstream AKT and ERK1/2 were almost completely inhibited. In previous studies, RON activation stimulated two signaling pathways: RAS-ERK1/2 and phosphoinositide 3-kinase (PI3K)–AKT. The RAS–ERK pathway is essential for regulating RON-mediated activities such as growth, survival, and invasiveness to cause epithelial-to-mesenchymal transition [27-29]. The PI3K-AKT pathway regulates RON-mediated cellular invasive growth [30].
Third, we confirmed the therapeutic efficacy of BMS-777607 in a mouse TNBC xenograft model. It is quite likely that BMS-777607 inhibits tumor growth and kills tumors both in vitro and in vivo. Moreover,some studies suggested inhibition of Axl is also main mechanism for BMS-777607 and Axl is highly expressed in the TNBC tumor cell line MDAM-BA-231 [21,31]. These findings lay the foundation for BMS-777607 targeting Tyrosine kinase to treat TNBC into clinical trials in the future.
In the following study, we selected two small-molecule inhibitors, i.e., INCB28060 and tivantinib, which inhibit MET alone and do not inhibit RON [22,23], and our experiments yielded near opposite results.
Tivantinib inhibits cell proliferation and induces apoptosis, whereas INCB28060 does not. In the cell migration experiment, the tivantinib group had a significantly higher inhibition rate than the INCB28060 group. Second, unlike BMS-777607 targeting of RON, INCB28060 and tivantinib inhibited the downstream ERK1/2 and AKT weaklier. Related studies have shown that, similar to RON, the signaling pathways downstream of MET have both RAS-ERK1/2 and PI3K-AKT pathways [7,27]. Finally, tivantinib inhibited MDA-MB-231 xenograft growth in the nude mice, whereas INCB28060 did not. Tivantinib also targets MET, where it can inhibit TNBC in vitro and in vivo.
On the other hand, INCB28060 was barely effective. Due to the multi-locus nature of small-molecule drugs, we believe that the anti-tumor effect of tivantinib is not MET-dependent and may be related to other targets. A recent study reported that the potent anti-tumor activity of tivantinib in hepatocellular carcinoma was achieved by targeting microtubules [32].
RON and MET can cross-talk and cooperate in intracellular signaling via transphosphorylation by forming specific RON-MET complexes [33]. This is consistent with the fact that the TKIs specifically targeting MET in the present study can slightly inhibit RON phosphorylation at cellular level. These basic research studies have also laid the foundation for the joint inhibition of RON and MET in TNBC such as BMS-777607 and tivantinib.
In summary, RON and MET are widely expressed in TNBC cancer tissues. This study demonstrates that RON and MET may be involved in an important process in TNBC malignant progression and can be important biomarkers in TNBC of poor prognosis. TKIs targeting RON and Met can inhibit the activation of the downstream signaling molecules, inhibit TNBC cell migration and proliferation, and increase TNBC cell apoptosis in vitro; in nude mouse xenograft models, the TKIs can significantly inhibit tumor growth and shrink tumor volume. TKIs targeting RON and MET have stronger drug development potential in TNBC treatment.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).
S1 Table.
Pairwise correlation of RON and MET
S2 Fig.
RON and MET expression in triple-negative breast cancer (TNBC) cells. (A) Triple-negative breast cancer cells (1×106 cells/mL) in 1 mL phosphate buffered saline (PBS) were incubated with 5.0 µg Zt/g4 (blue line) for 60 minutes. Isotope-matched mouse IgG (green line) and blank (black line) without antibody were used as the control. (B) TNBC cells (1×106 cells/mL) in 1 mL PBS were incubated in duplicate with BV510 mouse anti-human MET (red line) for 30 minutes. BV510 mouse IgG (green line) and blank (black line) without antibody were used as the control.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.


The work was supported by National Natural Science Foundation of China grant #81872883 (to HPY) and Zhejiang Major Medical Health & Sciences Technology Foundation Projects #WKJ-ZJ-13 and #2014C33204 (to HPY), and Zhejiang Provincial Natural Science Foundation of China grant #LY18H160014 (to XMX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Elixigen Corporation for reading our manuscript and providing native English professional support.

Fig. 1.
RON and MET expression in primary triple-negative breast cancer (TNBC) samples. Semiquantitative immunohistochemical staining was performed on 187 primary TNBC samples. Representative images showing negative staining and different levels of RON immunoreactivity are shown. A combined score of 2-4 was deemed weakly positive, while a combined score ≥ 5.0 was considered high expression or overexpression. (A) TNBC samples using mouse anti-RON mAb Zt/f2 for RON staining. (B) TNBC samples using rabbit anti-MET mAb for MET staining.
Fig. 2.
Kaplan-Meier plots with log-rank test of overall survival. Patients with RON high expression and MET high expression were considered to have high co-expression. +, high expression; –, low expression. Kaplan-Meier analysis showing that patients with triple-negative breast cancer with high RON (A), MET (B), and RON/MET co-expression (C, D) had shorter survival than patients with low expression (RON, p < 0.01; MET, p < 0.05; co-expression, p < 0.001).
Fig. 3.
Cytotoxic and apoptosis effects of BMS-777607, INCB28060, and tivantinib on triple-negative breast cancer cell lines. HCC1806, HCC2185, SUM52PE, and MDA-MB-231 cells (8,000 cells per well in 96-well plates in triplicate) were treated with different concentrations of BMS-777607, INCB28060, or tivantinib for 96 hours. (A) Cell Counting Kit-8 measurement of cytotoxic effects after exposure to tyrosine kinase inhibitors (TKIs). (B) Caspase-Glo 3/7 assay measurement of apoptosis effects after exposure to TKIs.
Fig. 4.
Tyrosine kinase inhibitors suppress MDA-MB-231 cell motility. MDA-MB-231 cells were serum starved overnight and scratched to generate artificial gaps. Cells were treated with different BMS-777607, INCB28060 or tivantinib in the serum-free medium. Cell motility was monitored and cells migrated into denuded area were scored. (A) Typical images of cell migration after tyrosine kinase inhibitor treatment (×50). Relative migration area as shown in the figure (%). (B) Open image area of cell migration. Data are from three independent experiments. ***The experimental group compared with the control group, p < 0.001.
Fig. 5.
Expression of RON and MET signaling pathways in MDA-MB-231 cells. Western blot analysis of whole cell lysate following tyrosine kinase inhibitor treatment. MDA-MB-231 cells were serum starved overnight, pretreated with BMS-777607, INCB28060, or tivantinib for 30 or 60 minutes, and stimulated with macrophage-stimulating protein (MSP) and hepatocyte growth factor (HGF) for 15 minutes. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.
Fig. 6.
RON and MET tyrosine kinase inhibitors inhibited triple-negative breast cancer xenograft growth in nude mice. (A) Average tumor volumes of HCC1806 and MDA-MB-231 xenografts. Cells were subcutaneously injected into the mouse left flank to establish xenograft models. All mice were observed, and the tumor volume were measured every 3 days. (B) Xenograft tumors obtained after the mice had been sacrificed.
Table 1.
Correlation between RON and MET expression and clinical characteristics of patients with triple-negative breast cancer
Factor Total, n (%) RON
RON and MET co-expression
Low High p-value Low High p-value Low High p-value
 Mean±SD 52.82±12.44 51.77 54.89 0.165 52.27 53.92 0.413 52.03 55.47 0.113
Lymph node metastasis
 Yes 48 (25.7) 28 20 0.175 33 15 0.678 37 11 0.999
 None 139 (74.3) 96 43 91 48 107 32
Distant metastasis
 Yes 19 (10.2) 11 8 0.413 11 8 0.413 13 6 0.348
 None 168 (89.8) 113 55 113 55 131 37
TNM stage
 Stage I 85 (45.5) 58 27 0.212 58 27 0.750 65 20 0.982
 Stage II 85 (45.5) 58 27 56 29 66 19
 Stage III 17 (9.1) 8 9 10 7 13 4
 Well 1 (0.5) 0 1 0.488 0 1 0.341 0 1 0.326
 Moderate 20 (10.7) 12 8 11 9 15 5
 Poor 147 (78.6) 99 48 100 47 114 33
 Unknown 19 (10.2) 13 6 13 6 15 4
 Chemotherapy 161 (86.1) 108 53 0.539 106 55 0.735 126 35 0.310
 None 26 (13.9) 16 10 18 8 18 8
Surgical procedures
 Conserving surgery 29 (15.5) 21 8 0.656 22 7 0.496 24 5 0.427
 Simple mastectomy 76 (40.6) 48 28 49 27 55 21
 Radical mastectomy 82 (43.9) 55 27 53 29 65 17
Tumor size (cm3)
 ≥ 5 88 (47.1) 57 31 0.675 54 34 0.177 66 22 0.539
 < 5 99 (52.9) 67 32 70 29 78 21


1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90.
crossref pmid pmc pdf
2. Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer. 2018;9:296–303.
crossref pmid pmc
3. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–57.
crossref pmid pdf
4. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993;8:1195–202.
5. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009;19:542–51.
crossref pmid
6. Yao HP, Zhou YQ, Zhang R, Wang MH. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer. 2013;13:466–81.
crossref pmid pdf
7. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103.
crossref pmid pdf
8. Yao HP, Zhuang CM, Zhou YQ, Zeng JY, Zhang RW, Wang MH. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor. Curr Cancer Drug Targets. 2013;13:686–97.
crossref pmid
9. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, et al. Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998;16:2927–33.
crossref pmid pdf
10. Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC, et al. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene. 2014;33:1429–37.
crossref pmid pdf
11. Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, et al. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep. 2014;6:141–54.
crossref pmid pmc
12. Kretschmann KL, Eyob H, Buys SS, Welm AL. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets. 2010;11:1157–68.
crossref pmid
13. Sharma S, Zeng JY, Zhuang CM, Zhou YQ, Yao HP, Hu X, et al. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther. 2013;12:725–36.
crossref pmid
14. Bieniasz M, Radhakrishnan P, Faham N, De La OJ, Welm AL. Preclinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts. Clin Cancer Res. 2015;21:5588–600.
crossref pmid pmc
15. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005;11:2222–8.
crossref pmid
16. Lindemann K, Resau J, Nahrig J, Kort E, Leeser B, Annecke K, et al. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 2007;51:54–62.
crossref pmid
17. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 2009;106:12903–8.
crossref pmid pmc
18. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 2009;106:12909–14.
crossref pmid pmc
19. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.
crossref pmid pdf
20. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem. 2009;52:1251–4.
crossref pmid
21. Lauter M, Weber A, Torka R. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation. Cell Commun Signal. 2019;17:59.
crossref pmid pmc pdf
22. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17:7127–38.
crossref pmid
23. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1544–53.
crossref pmid
24. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 2007;213:402–11.
crossref pmid
25. Suthe SR, Yao HP, Weng TH, Hu CY, Feng L, Wu ZG, et al. RON receptor tyrosine kinase as a therapeutic target for eradication of triple-negative breast cancer: efficacy of anti-RON ADC Zt/g4-MMAE. Mol Cancer Ther. 2018;17:2654–64.
crossref pmid
26. Tsimafeyeu I, Stepanova E, Khochenkov D, Murillo G, Lapina N, Gavrilova E, et al. Preclinical characterization of alofanib, a novel allosteric FGFR2 inhibitor. Ann Oncol. 2016;27(Suppl 9):ix45–51.
crossref pdf
27. Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S, et al. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. J Biol Chem. 2011;286:32762–74.
crossref pmid pmc
28. Li BQ, Wang MH, Kung HF, Ronsin C, Breathnach R, Leonard EJ, et al. Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor. Biochem Biophys Res Commun. 1995;216:110–8.
crossref pmid
29. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell. 2009;35:511–22.
crossref pmid pmc
30. Wang MH, Montero-Julian FA, Dauny I, Leonard EJ. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene. 1996;13:2167–75.
31. Torka R, Penzes K, Gusenbauer S, Baumann C, Szabadkai I, Orfi L, et al. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia. 2014;16:301–18.
crossref pmid pmc
32. Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y, Li J, et al. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:118.
crossref pmid pmc
33. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000;19:3041–9.
crossref pmid pdf
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI